



Agenda

➤ Thursday, 5th December 2024

Welcome & Introduction

- 09:00 – 09:30 *Registration & Welcome Coffee*
- 09:30 – 09:40 Welcome by the Charité Representatives
- 09:40 – 10:05 **ReSHAPE the immune balance - several steps forward along the path**
Petra Reinke / Charité – Universitätsmedizin Berlin, Germany

Next generation Treg development, product characterization and biomarker platform

- 10:05 – 10:25 **Gene editing strategies to create next generation of cell-and gene therapies for clinical application**
Dimitrios L. Wagner / Charité – Universitätsmedizin Berlin / Berlin Institute of Health at Charité, Germany / Baylor College of Medicine, Houston, USA
- 10:25 – 10:45 **Generating and Applying Epigenomic Knowledge to Improve Therapeutic Cell Products**
Julia Polansky / Berlin Institute of Health at Charité, Germany
- 10:45 – 11:10 **Benefits of imaging cell-based immunotherapies**
Invited Speaker: Gilbert Fruhwirth / School of Cancer and Pharmaceutical Sciences, King's College London, UK
- 11:10 – 11:30 **Next generation Treg development platform for tissue specific CAR Treg**
Elmar Jäckel / Medizinische Hochschule Hannover, Germany / Ajmera Transplant Centre, University Health Network, Toronto, Canada
- 11:30 – 11:55 **ID card of the cell product and therapy response monitoring**
Hans-Dieter Volk / Charité – Universitätsmedizin Berlin / CheckImmune GmbH, Germany
- 12:00 – 12:45 *Lunch break and **B2Match** session*

Improvement of in vivo engraftment of adoptively transferred Tregs (part 1)

- 12:45 – 13:10 **Combination cell therapy with recipient Tregs and donor bone marrow in HLA-mismatched kidney transplantation**
Invited Speaker: Thomas Wekerle / Medical University of Vienna, Austria
- 13:10 – 13:30 **The two study – transplantation without over immune suppression**
Fadi Issa / Nuffield Department of Surgical Sciences / University of Oxford, UK





Agenda

- 13:30 – 13:50 **ProTreg Trial – A phase I/IIa study to investigate the safety and tolerability of Tregs as an adjunctive therapy in CD kidney recipients following anti-thymocyte (ATG) induction therapy**
Petra Reinke / Charité – Universitätsmedizin Berlin / Berlin Institute of Health at Charité, Germany
- 13:50 – 14:10 **LiveTreg Trial - A Phase I/IIa open label single ascending dose study to assess safety and tolerability of regulatory T cells to promote discontinuation of tacrolimus monotherapy in liver transplant recipients**
Leila Amini / Charité – Universitätsmedizin Berlin, Germany
- 14:10 – 14:30 **Advancing CD8+ Treg cell therapy to the clinic: The 8-Treg Trial**
Carole Guillonon / INSERM Nantes, France
- 14:30 – 14:50 **TregTacRes Trial - An open-label, active-controlled single ascending dose, first-in-human study to investigate the safety and tolerability of TregTacRes as an adjunctive therapy in living-donor kidney recipients**
Petra Reinke / Charité – Universitätsmedizin Berlin, Germany
- 14:50 – 15:05 **Patient organization view on CGT regarding hope and concerns and expectations towards clinical scientists, regulatory authorities and EU commission**
Invited Speaker: Mónica Suengas, Juan Carlos Julián Mauro / EKPF European Kidney Patients Federation
- 15:05 – 15:20 *Coffee break and B2Match session*

Improvement of in vivo engraftment of adoptively transferred Tregs (part 2)

- 15:20 – 15:45 **Resetting autoimmunity in immune-mediated inflammatory disease**
Invited Speaker: Gerhard Krönke / Charité – Universitätsmedizin Berlin, Germany
- 15:45 – 16:10 **Treatment of type 1 diabetes with Tregs – towards marketing authorization**
Invited Speaker: Piotr Trzonkowski / Medical University of Gdansk, Poland
- 16:10 – 16:30 **Accelerate and de-risk EU ATMP development - Joint4ATMP**
Invited Speaker: Annette Künkele / Charité – Universitätsmedizin Berlin, Germany
- 16:30 – 16:50 **Health technology assessment – an important tool towards the market for ATMP's**
Catapult Cell and Gene Therapy, UK; tbc
- 16:50 – 17:00 **Closing remarks**
Abul Abbas, Spokesperson of the ReSHAPE EAB
- 17:00 – 19:00 *B2Match session*

